Sarepta Therapeutics makes sense of antisense. A developer of biopharmaceutical compounds, the company's investigational therapies are based on its RNA-based antisense drug technology, which can halt disease processes at the genetic level. The drug developer is working on drugs that could potentially be used in the treatment of a wide range of conditions, including genetic and infectious diseases. Sarepta has research and development programs for targets including the Ebola and Marburg viruses, dengue fever, anthrax, and pandemic influenza. In 2016 the FDA granted tentative approval for Sarepta's Duchenne muscular dystrophy drug, eteplirsen. It was the first FDA approval of a treatment for that condition.